Physician profile
Malorie Holmes
NPI 1659804052
$8,155.18
in general payments reported to CMS, 2019-2025
16 companies · $163 in 2025
The $163 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $404 · 2023: $1,211 · 2024: $6,377 · 2025: $163.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,025 · Food and Beverage: $2,402 · Travel and Lodging: $1,168 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,025.00 |
| Food and Beverage | $2,402.34 |
| Travel and Lodging | $1,168.31 |
| Education | $155.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,971.72 | 2023-2024 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $407.92 | 2023-2025 | |
| Horizon Therapeutics Plc | $305.17 | 2022-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $296.40 | 2022-2024 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $234.55 | 2022-2024 | Veltassa |
| Glaxosmithkline, LLC. | $153.23 | 2023 | Benlysta |
| Opko Pharmaceuticals, LLC | $150.45 | 2023-2025 | Rayaldee |
| Otsuka America Pharmaceutical, INC. | $110.86 | 2023-2024 | Jynarque |
| Fresenius USA Marketing, INC. | $110.53 | 2022-2024 | Velphoro |
| Travere Therapeutics, INC. | $94.82 | 2022-2025 | Thiola, Filspari |
| Calliditas Therapeutics US INC. | $87.43 | 2023-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $83.93 | 2024-2025 | |
| Ardelyx, INC. | $51.01 | 2024-2025 | Ibsrela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.35 | 2023 | Jardiance |
| Daiichi Sankyo INC. | $28.07 | 2023 | Injectafer |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $19.74 | 2025 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Malorie Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.